RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to ...

September marks Awareness Month, and this year, the INOVA Schar Adult Center hosted a pivotal town meeting to unite advocates ...

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...

This investor is excited about the transformational potential of one growth stock that he's been eyeing up for his portfolio.

BioCentriq has appointed Syed T. Husain as its new chief executive officer (CEO), and as a member of the Board of Directors.

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

By Andie Bernhardt Click here for updates on this story MILWAUKEE (WDJT) — September is Sickle Cell Awareness Month. Sickle cell is a painful blood disease that’s inherited and affects thousands of ...

GC Therapeutics, Inc. (GCTx), announced its launch today to scale and unlock the next generation of cell therapy. Invented and developed by a world-class team of scientists in the lab of professor ...

Of course, GC Therapeutics could also mean gene and cell therapeutics ... “These are the disease areas that really we believe ...

The TRIM21 therapies have been shown to remove toxic tau proteins and reduce symptoms of neurodegeneration in mice.

Oxford Biomedica has rebranded as OXB to reinforces the firm’s transformation into a global pure-play cell and gene therapy ...